{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:38:26Z","timestamp":1783517906042,"version":"3.55.0"},"reference-count":81,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In the field of antithrombotics, precision medicine is of particular interest, as it may lower the incidence of potentially life-threatening side effects. Indeed, antiplatelet drugs such as P2Y12 inhibitors are one of the most common causes of emergency admissions for drug-related adverse events. The last ten years have seen a continuous debate on whether platelet function tests (PFTs) should be used to tailor antiplatelet drugs to cardiovascular patients. Large-scale randomized studies investigating the escalation of antiplatelet therapies according to the results of PFTs were mostly negative. Potent P2Y12 inhibitors are recommended as a first-line treatment in acute coronary syndrome patients, bringing the bleeding risk at the forefront. De-escalation from prasugrel or ticagrelor to clopidogrel is now considered, with or without the use of a PFT. This review covers recent advances in escalation and de-escalation strategies based on PFTs in various clinical settings. It also describes the main features of the most popular platelet function tests as well as the potential added value of genetic testing. Finally, we detail practical suggestions on how PFTs could be used in clinical practice.<\/jats:p>","DOI":"10.3390\/jcm9010194","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T04:05:51Z","timestamp":1578888351000},"page":"194","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1546-0774","authenticated-orcid":false,"given":"Pierre","family":"Fontana","sequence":"first","affiliation":[{"name":"Geneva Platelet Group, Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland"},{"name":"Division of Angiology and Haemostasis, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7528-7363","authenticated-orcid":false,"given":"Jean-Luc","family":"Reny","sequence":"additional","affiliation":[{"name":"Geneva Platelet Group, Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland"},{"name":"Division of General Internal Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cts.12446","article-title":"Personalized Medicine in Europe","volume":"10","author":"Nimmesgern","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMp1613224","article-title":"Beyond Genes and Molecules-A Precision Delivery Initiative for Precision Medicine","volume":"376","author":"Parikh","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40262-019-00792-y","article-title":"Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants","volume":"58","author":"Terrier","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1001\/jama.2016.16201","article-title":"US Emergency Department Visits for Outpatient Adverse Drug Events, 2013\u20132014","volume":"316","author":"Shehab","year":"2016","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/ehjcvp\/pvw005","article-title":"P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: Use, patient selection, and outcomes from contemporary European registries","volume":"2","author":"Zeymer","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jth.13316","article-title":"Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry","volume":"14","author":"Alexopoulos","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.amjcard.2015.05.036","article-title":"Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention with Drug-Eluting Stents","volume":"116","author":"Matteau","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.jacc.2011.02.011","article-title":"2011 ACCF\/AHA focused update incorporated into the ACC\/AHA 2007 Guidelines for the Management of Patients with Unstable Angina\/Non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons","volume":"57","author":"Wright","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0049-3848(91)90085-B","article-title":"Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients","volume":"63","author":"Grotemeyer","year":"1991","journal-title":"Thromb. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0049-3848(93)90164-J","article-title":"Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients","volume":"71","author":"Grotemeyer","year":"1993","journal-title":"Thromb. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/01.CIR.103.25.3051","article-title":"Genetic and environmental contributions to platelet aggregation: The Framingham heart study","volume":"103","author":"Larson","year":"2001","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1161\/01.ATV.19.4.1142","article-title":"Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: The Framingham Offspring Study","volume":"19","author":"Feng","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2002-07-2149","article-title":"An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN","volume":"101","author":"Dupont","year":"2003","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2174\/1381612822666151208122845","article-title":"Pharmacogenomics of Oral Antithrombotic Drugs","volume":"22","author":"Storelli","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2007.02812.x","article-title":"The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score","volume":"6","author":"Geisler","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1538-7836.2010.04063.x","article-title":"Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study","volume":"8","author":"Fontana","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1161\/01.CIR.0000106904.80795.35","article-title":"P2Y12 H2 haplotype is associated with peripheral arterial disease: A case-control study","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/j.1538-7836.2006.02113.x","article-title":"Role of the P2Y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects","volume":"4","author":"Bura","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/CIRCGENETICS.109.861799","article-title":"Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions","volume":"2","author":"Rudez","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/j.1538-7836.2011.04409.x","article-title":"Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study","volume":"9","author":"Fontana","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lewis, J.P., Backman, J.D., Reny, J.L., Bergmeijer, T.O., Mitchell, B.D., Ritchie, M.D., Dery, J.P., Pakyz, R.E., Gong, L., and Ryan, K. (2019). Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients. Eur. Heart J. Cardiovasc. Pharmacother.","DOI":"10.1093\/ehjcvp\/pvz045"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.acvd.2018.10.004","article-title":"Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR)","volume":"112","author":"Godier","year":"2019","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1538-7836.2006.01867.x","article-title":"Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers","volume":"4","author":"Fontana","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","article-title":"Drug resistance and pseudoresistance: An unintended consequence of enteric coating aspirin","volume":"127","author":"Grosser","year":"2013","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2015.05.012","article-title":"The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin","volume":"66","author":"Patrono","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jprot.2018.09.007","article-title":"A high glucose level is associated with decreased aspirin-mediated acetylation of platelet cyclooxygenase (COX)-1 at serine 529: A pilot study","volume":"192","author":"Finamore","year":"2019","journal-title":"J. Proteom."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","article-title":"Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance","volume":"113","author":"Frelinger","year":"2006","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1538-7836.2008.02897.x","article-title":"Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A systematic review and meta-analysis","volume":"6","author":"Reny","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1540-8183.2011.00670.x","article-title":"Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention","volume":"24","author":"Gaglia","year":"2011","journal-title":"J. Int. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1160\/TH11-03-0202","article-title":"Prevalence of poor biological response to clopidogrel: A systematic review","volume":"107","author":"Mallouk","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11239-014-1119-9","article-title":"Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction","volume":"39","author":"Perl","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/jth.12907","article-title":"High on-treatment platelet reactivity with ticagrelor versus prasugrel: A systematic review and meta-analysis","volume":"13","author":"Lemesle","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Winter, M.P., Schneeweiss, T., Cremer, R., Biesinger, B., Hengstenberg, C., Pruller, F., Wallner, M., Kolesnik, E., von Lewinski, D., and Lang, I.M. (2019). Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur. J. Clin. Investig., e13102.","DOI":"10.1111\/eci.13102"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","article-title":"Association of laboratory-defined aspirin resistance with a higer risk of recurrent cardiovascular events. A systematic review and meta-analysis","volume":"167","author":"Snoep","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","article-title":"Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization","volume":"120","author":"Frelinger","year":"2009","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1161\/CIRCULATIONAHA.111.085464","article-title":"Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients: Results of the Antiplatelet Drug Resistances and Ischemic Events Study","volume":"125","author":"Reny","year":"2012","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13177","DOI":"10.1038\/s41598-019-49123-y","article-title":"Association among PlA1\/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e000703","DOI":"10.1161\/JAHA.112.000703","article-title":"High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients with Stable Coronary Artery Disease: Results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)","volume":"1","author":"Pettersen","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1538-7836.2010.03809.x","article-title":"Clinical implications of clopidogrel non-response in cardiovascular patients: A systematic review and meta-analysis","volume":"8","author":"Combescure","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ahj.2010.06.004","article-title":"Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis","volume":"160","author":"Aradi","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1161\/CIRCULATIONAHA.112.112094","article-title":"Platelet function testing in patients with coronary artery disease: Is the Who and the When any clearer than the What and the What then?","volume":"125","author":"Rade","year":"2012","journal-title":"Circulation"},{"key":"ref_57","first-page":"844","article-title":"Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data","volume":"115","author":"Reny","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jacc.2014.05.049","article-title":"Aspirin treatment and outcomes after percutaneous coronary intervention: Results of the ISAR-ASPI registry","volume":"64","author":"Mayer","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis","volume":"103","author":"Bonello","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): An open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Wang, Y., Wu, Y., Huang, C., Yan, H., Zhu, W., Xu, W., Zhang, L., and Zhu, J. (2017). Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord., 17.","DOI":"10.1186\/s12872-017-0582-6"},{"key":"ref_66","unstructured":"Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R.F., Deaton, C., and Cuisset, T. (2019). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/eurheartj\/ehv511","article-title":"Stent thrombosis and restenosis: What have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","article-title":"Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis","volume":"51","author":"Antman","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1160\/TH15-11-0864","article-title":"Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients","volume":"116","author":"Nagatsuka","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1253\/circj.CJ-18-1386","article-title":"Association of CYP2C19 Polymorphisms with Clopidogrel Reactivity and Clinical Outcomes in Chronic Ischemic Stroke","volume":"83","author":"Tanaka","year":"2019","journal-title":"Circ. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.jcin.2017.08.044","article-title":"Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study","volume":"10","author":"Deharo","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 Inhibitor Monotherapy vs. Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1055\/s-0038-1667337","article-title":"Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy","volume":"118","author":"Gross","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e000131","DOI":"10.1161\/JAHA.112.000131","article-title":"Tailored Thienopyridine therapy: No urgency for CYP2C19 genotyping","volume":"2","author":"Fontana","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.jcin.2019.07.034","article-title":"Platelet Function Testing or Genotyping: Which Should We Trust?","volume":"12","author":"Fontana","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.112.105908","article-title":"Guided antithrombotic therapy: Current status and future research direction: Report on a National Heart, Lung and Blood Institute working group","volume":"126","author":"Fuster","year":"2012","journal-title":"Circulation"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/1\/194\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:04:26Z","timestamp":1760364266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/1\/194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["jcm9010194"],"URL":"https:\/\/doi.org\/10.3390\/jcm9010194","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737217341.793570105","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]}}}